Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced key executive appointments designed to accelerate the ...
News Medical on MSN1d
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AIInsilico Medicine pulls back the curtain on developmental timelines, highlighting a ~13 month average timeline to reach developmental candidate (DC) nomination across 22 programs. Insilico’s QPCTL ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...
Sentinel & Enterprise on MSN5dOpinion
Editorial: Psychedelics lobby turns to lawmakers’ clinically-based billsPlant-based medicine advocates haven’t given up their efforts to see that therapeutic method take root. Question 4, defeated ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
Isotopes Market There is an increasing trend in the use of rare stable isotopes, such as 13C, 15N, and 18O, as tracers in scientific resear ...
Ruby Jackson speaks to the psychiatrist researching the therapeutic potential of psychedelics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback